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ureters in each group. Biocompatibility was assessed by his-
topathological grading.
Results In all cases, the BUS was only visible during the 
first 24 h on X-ray, and in all cases the BUS was completely 
degraded in urine after 10 days, as confirmed on necropsy. 
During the degradation process, the mechanical properties 
of the BUS decreased, while the commercial ureteral stents 
remained constant. At all time-points after stent insertion, 
the level of hydronephrosis was minimal. Overall, animals 
stented with BUS had an average grade of hydronephrosis 
which was lower compared to the controls. The BUS showed 
better pathological conditions, and hence better biocompat-
ibility when compared with commercial stents.
Conclusions Notwithstanding the limitations of the present 
study, the in vivo testing of our novel natural origin poly-
mer-based BUS suggests this device to feature homogeneous 
degradation, good urine drainage, and high biocompatibility. 
Next steps will be to increase its stability, and to improve 
the radiopacity without compromising its degradation. Ulti-
mately, clinical studies will be required to determine the 
safety and feasibility of its use in humans.
Keywords Biodegradable · Polymers · Ureteral stent · 
Ureteroscopy
Introduction
Ureteral stents are routinely used in daily urological practice 
for a variety of indications. Nevertheless, it is widely rec-
ognized that these medical devices can produce significant 
symptoms, like infection, encrustation, patient discomfort 
[1]. Moreover, a cystoscopy procedure is usually required for 
stent removal. Eventually, the so-called “forgotten stent syn-
drome” can lead to kidney loss or even death [2]. Because 
Abstract 
Purpose To perform an in vivo assessment of a newly 
developed biodegradable ureteral stent (BUS) produced with 
natural-based polymers.
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bining the injection process with the use of supercritical 
fluid technology. Study was conducted at ICVS—Univer-
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pigs were used. In seven animals, the experimental BUS 
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Tissues were compared between the stented groups as well 
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of these issues, much research over the past two decades 
has been focused on “biodegradable” materials to minimize 
stent-related morbidity, and to avoid a second procedure for 
stent removal [3].
Several biodegradable ureteral stents (BUS) have been 
reported, but all of them have failed because of poor bio-
compatibility or incomplete degradation [4, 5]. The main 
challenge remains to have a uniform and homogenous degra-
dation, preventing the formation of fragments that can cause 
obstruction. We recently described a BUS produced with 
natural-based polymers [6].
In the present study, we assessed in vivo (in a porcine 
model) this newly developed BUS, by comparing its degra-
dation, mechanical properties, drainage, physiological and 
histological features with those of a commercially available 
ureteral stent.
Methods
BUS technology
The BUS described in this study is based on a patented 
technology combining the injection process with the use of 
supercritical fluid technology. Briefly, an aqueous solution 
of gelatin—alginic-acid sodium salt and bismuth carbonate 
basic (65:30:5 wt%)—is prepared. After obtaining a homog-
enous solution, 15 mM of a crosslinking agent (genipin) is 
added. The solution is then injected in a mold to obtain a 
6-Fr ureteral stent with the total length of 20 cm, wall thick-
ness of 500 µm and internal diameter of 1000 µm. Super-
critical technology is the used to dry the stent. Supercritical 
technology is emerging as an alternative to conventional 
materials’ processing methods for the preparation of three-
dimensional structures and injectable particles suitable to be 
used in regenerative medicine [7]. The coating is performed 
by immersion into a 10 wt% solution of polycaprolactone 
resin 787 with 2 wt% of bismuth carbonate basic in chloro-
form. Last, stent is sterilized with ethylene oxide at 42 °C 
for 3 h.
Experimental protocol
The study was conducted at ICVS—University of Minho 
(Braga, Portugal) in accordance with its internal ethical 
protocol for animal experiments. A total of ten domestic 
pigs were used. All procedures were performed under gen-
eral anesthesia and mechanical ventilation. After emptying 
the bladder, a semi rigid 7-Fr ureteroscope (Karl Storz, 
Tuttlingen, Germany) was inserted through the urethra. 
A 0.035″ flexible tip guidewire  (AQUATRACK® Hydro-
philic Nitinol,  Cordis®, Johnson & Johnson) was inserted, 
and then stent was passed over the guide wire into the 
kidney. In seven animals, the experimental BUS stent 
was inserted, whereas in the remaining a commercially 
available stent was used (6-Fr  Biosoft® duo stents, Porges 
Coloplast, Denmark). Correct positioning of stents was 
confirmed by X-ray. Post-stenting intravenous pyelogram 
(IVP) was used to evaluate the degree of hydronephrosis 
at days 0, 1, 5 and 10 [5].
After maximum 10 days, animals were killed and nec-
ropsy was performed. Among the seven pigs stented with 
the BUS, one died for pre-existing pneumonia at day 5, 
and one was killed at day 7. In both cases, the BUS was 
retrieved and used for analysis. A midline incision was 
carried out to excise the kidneys, ureters and bladder en 
bloc. The kidneys and ureters were measured and a rep-
resentative section of each organ was fixed in 10% for-
malin and stained with hematoxylin–eosin and Masson’s 
trichrome. Tissues were compared between the stented 
groups (biodegradable vs commercial stents) as well as 
between the non-stented contralateral (control) ureters 
and stented ureters in each group. Biocompatibility was 
assessed by histopathological grading, as suggested by 
Chew et al. [8] (from Grade 0-no inflammation to Grade 
3-severe edema, congestion, inflammation).
The in vivo stent degradation was measured as function 
of the weight loss. Stents were first measured at baseline in 
“dry” condition. When removed from the in vivo model, 
it was dried and then measured. The weight loss of stents 
was calculated according to the following equation:
where  Wf is the final weight of the stent (dried after immer-
sion/placement) and Wi is the initial weight of the stent.
The tensile properties of the BUS were tested at days 
0, 5 and 7. The testing at days 5 and 7 was performed on 
the stents retrieved from the one pig died for pneumonia 
at day 5, and the one killed at day 7. Tensile mechanical 
analysis was performed by an INSTRON 5540 (Instron Int. 
Ltd, High Wycombe, UK) universal testing machine with 
a load cell of 1 kN. The load was placed midway between 
the supports with a span (L) of 30 mm. The crosshead 
speed was 1:5 mm min−1. For each condition, the speci-
mens were loaded until core break. The in vivo recovered 
stents were cut into equal parts along their length and com-
pared. The tensile properties of BUS were compared with 
the control group used in this study from the data of our 
previous study [9].
All quantitative data are presented as mean ± stand-
ard deviation (SD). Statistical analysis was performed 
using Graph Pad Prism 6.00 software (San Diego, USA). 
Statistical significances (*p  ≤  0.05, **p  ≤  0.01 and 
***p ≤ 0.001) were determined using one-way analysis 
(1)%Weight loss =
Wf −Wi
Wi
× 100,
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of variance (ANOVA) for an average of three to twelve 
replicates, followed by post hoc Tukey’s test for all pair-
wise mean comparisons. Hydronephrosis scores with time 
were compared using two-way repeated measures ANOVA 
followed by the Bonferroni post test.
Results
In all cases, the BUS was only visible during the first 24 h 
on X-ray, and in all cases the BUS was completely degraded 
(100% weight loss) in urine after 10 days, as confirmed on 
necropsy. In the pig killed early at day 7, the mass reduction 
of the BUS was 38% (Fig. 1). Homogeneous degradation by 
erosion along the entire stent surface was visualized, while 
the lumen remained patent. During the degradation process, 
the mechanical properties of the BUS decreased, while the 
commercial ureteral stents remained constant. BUS dem-
onstrated to have lower maximum tensile strain and higher 
stiffness compared to the commercial stent (Fig. 2). At all 
time-points after stent insertion, the level of hydronephro-
sis—as based on the IVP assessment—was grade 2 or lower. 
Overall, animals stented with BUS had an average grade of 
hydronephrosis which was lower compared to the controls 
Fig. 1  a all of the five BUS 
were completely degraded 
(100% weight loss) in urine 
after 10 days; b the BUS 
retrieved after 5 days was intact 
with a weight loss of 24%; c 
the BUS retrieved at day 7 was 
also intact with a mass reduced 
by 38%
Fig. 2  The in  vivo tensile mechanical properties, namely maxi-
mum tensile strain (%) and also the stiffness—the Young’s modulus 
(MPa)—of the BUS during the degradation process are presented 
here. BUS showed less 40%, at day 5 and 65%, at day 7 of maximum 
tensile strain after in vivo degradation. In terms stiffness, BUS were 
significantly more resistant than the control until day 7, the time that 
both stents presented similar values. During the degradation process, 
the mechanical properties of the BUS decreased, while the commer-
cial ureteral stents remained constant. BUS demonstrated to have 
lower maximum tensile strain and higher stiffness compared to the 
commercial stent
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(Fig. 3). Based on histopathological grades for nephropa-
thy and ureteral pathology, kidneys and ureters stented with 
BUS showed better pathological conditions, and hence 
better biocompatibility when compared with commercial 
stents (Table 1). No significant differences were observed 
between the stented kidney and non-stented and between the 
two types of stents in terms of ureteral width (Fig. 4). Not 
surprisingly, histological analysis revealed greater changes 
in stented ureters than in non-stented ureters in each group. 
Overall, no significant inflammatory or necrotic cells were 
found in both groups (Fig. 5).
Discussion
Fragments from stent degradation still represent an issue 
that needs to be overcome, and this is the main reason why 
biodegradable stents are not available in the market yet. 
Fragments can act as a nucleation point for bacterial adhe-
sion and/or encrustation development leading to further 
complications [10]. Chew et al. developed a biodegradable 
stent—Uriprene™—that was investigated in vivo by assess-
ing degradation time, and physiological and histological 
responses in a porcine model [5]. Zhang et al. developed a 
similar glycolic–lactic acid fiber based BUS, and reported 
results in vivo, in a canine model [11]. Both studies pre-
sented good results regarding the degradation and biocom-
patibility; however, upon degradation they reported frag-
ments of the stent in the renal pelvis and bladder. The time 
of degradation of these glycolic–lactic acids-based BUSs 
was around 4 weeks. Hjdinjak et al. designed an experiment 
to simulate the physical forces that may lead to material 
fatigue of the stent. From their results, it appeared that stent 
fractures can be avoided by observing a maximum indwell-
ing time of 6–8 weeks [12]. In clinical practice, temporary 
ureteral stents are generally kept up to 4 weeks after their 
insertion, depending on the indication. In our study, the time 
of stent degradation was shorter (10 days), which can limit 
the therapeutic applications of this device now. However, 
modification of the stent formulation, incorporating new 
polymers or different cross-linking, may result in longer 
indwelling times. Overall, animals stented with BUS present 
less degree of hydronephrosis compared with the controls. It 
is well documented that placement of conventional ureteral 
stents may result in a certain level of hydronephrosis [13]. 
While ureteral stents can alleviate obstruction, the urine flow 
is not the same as freely as that in a non-stented ureter [14]. 
The degradation process of BUS showed no effect on the 
urine flow, and it did not increase the hydronephrosis. Inter-
estingly, IVP findings suggested that BUS might provide 
Fig. 3  a representative image of pyelogram at day 10 after BUS 
degradation; b hydronephrosis score obtained for all animals stented 
with BUS and commercial stents. At all time-points after stent inser-
tion, the hydronephrosis level of all pigs was not higher than grade 
2. Overall, animals stented with BUS had an average of slightly less 
hydronephrosis compared with the control, commercial stent
Table 1  Biocompatibility parameters of BUS and commercial stents 
group in the kidney and the ureters
Data presented as mean ± SD
*Significant
Group BUS Commercial p value
Nephropathy 0.17 ± 0.37 0.67 ± 0.47 0.24
Ureteral pathology 0.33 ± 0.47 1.67 ± 0.33 0.04*
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better flow than control stent. This can be explained by the 
water uptake capacity of hydrogel-based materials which has 
higher absorbing properties then the conventional material 
used in the non-BUSs [15].
Ureteral stents are in close contact with uroepithelium 
and because of, therefore, their biocompatibility is an 
important feature [11]. Based on histopathological grades 
for nephropathy and ureteral pathology, kidneys and ureters 
stented with BUS shown better pathological conditions, and 
hence better biocompatibility. Overall, the ureteral width of 
BUS-stented ureters was not statistically significantly larger 
when compared to the non-stented ureter. Similar results 
were observed by Chew et al. demonstrating the ability of 
BUSs to be less abrading when compared with conven-
tional ureteral stents [5]. It is well documented that the 
placement of commercial ureteral stents can cause irritation 
of the ureteral epithelium [16]. The ureteral epithelium after 
BUS placement and degradation remained intact without 
any major change compared to the control. The thickness 
of ureter mucosa remained similar and no inflammation 
or hydronephrosis was observed. In contrast, commercial 
stent showed to cause some degree of edema and epithe-
lium destruction, as also observed by others [5, 16]. Another 
study on biodegradable stents developed by using different 
materials showed severe inflammatory reaction, with stent 
material entrenched in the ureteral wall [4]. This reaction 
was not observed in our study. The characteristics of the 
base material of the stents are essential for a good preserva-
tion of ureteral histopathology. Our BUS is a hydrogel-based 
stent, shown to be ureteral urothelium-friendly material, and 
Fig. 4  Overall the ureteral width of BUS-stented ureters was not sta-
tistically significantly larger when compared to the non-stented ureter. 
In contrast, commercial stented ureters were statistically significantly 
greater when compared to the ureters non-stented, in mid (p ≤ 0.01), 
upper and distal (p ≤ 0.001) ureter sections
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the degradation products not induced any ureteral inflam-
matory response. Hydrogel-based materials have been used 
for conventional stents to reduce the stent-related problems; 
however, full hydrogel stents have not yet been introduced 
in the market yet [3].
Our study has some limitations, including the small 
sample, and the use of only one type of commercial stent 
as a control. Next steps will be to increase the stability of 
the BUS in vivo, improve the radiopaque features while 
the degradation by erosion is not compromised, and it 
occurs without fragments of the stent. Moreover, modi-
fication of the stent formulation, incorporating new poly-
mers or different cross-linking, should ideally result in 
longer (more than 10 days) indwelling times, allowing for 
a broader clinical application of the product. Ultimately, 
Fig. 5  Representative HE (Hematossilin Eosin) and MT (Massons trichrome stain) images of the ureters. It is possible to appreciate the differ-
ences in the mucosa thickness between the control and the commercial ureteral stent group
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clinical studies will be required to determine the safety and 
feasibility of its use in humans.
Conclusions
Herein, we describe the development and in vivo testing 
of a novel natural origin polymer-based BUS. This device 
presents a homogeneous degradation by surface erosion, 
good physiological and histopathological response, effec-
tive urine drainage, and high biocompatibility. Overall, this 
novel BUS can be regarded as a significant advance in the 
field. Nevertheless, further studies are needed to address cur-
rent limitations of this product and to prove its safety in the 
clinical setting.
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